Antimicrobial peptide PL-18 for treating vaginal infections
ProteLight Biopharma's PL-18 antimicrobial peptide offers a novel treatment for Vulvovaginal Candidiasis (VVC) and Recurrent VVC, with broad-spectrum activity and reduced resistance risk. Phase Ib trials completed; seeking partners for clinical development and commercialization.
Overview
ProteLight Biopharma introduces PL-18, an innovative antimicrobial peptide designed to treat Vulvovaginal Candidiasis (VVC) and manage Recurrent VVC. The unique mechanism of action of PL-18 provides broad-spectrum activity against various pathogens, making it a promising alternative to traditional antibiotics. This solution aims to offer effective treatment with fewer side effects and a reduced risk of resistance, addressing a critical need in managing recurrent vaginal infections.
Technical specifications
Key features:
- Broad-spectrum antimicrobial activity against a wide range of pathogens
- Unique mechanism of action that reduces the risk of resistance development
- Potential for fewer side effects compared to traditional antibiotics
This peptide is particularly aimed at patients suffering from Recurrent VVC, providing a more sustainable and effective therapeutic option.
Technology readiness level
PL-18 has successfully completed phase Ib clinical trials in China and is advancing to phase II. ProteLight is actively seeking global and regional partners to further clinical development and commercialization efforts.
About Protelight
specializes in both the R&D and manufacture of peptide and chemical drugs; focus areas include treatments for antimicrobial resistance, along with therapies for oncology and autoimmune diseases
delivered to your inbox.